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Oncogenes and tumor suppressor genes are impli-
cated in the regulation of the angiogenic switch.
Much of the data accumulated to date uses NIH 3T3
cells, which are de®cient in the tumor suppressor
gene p16, as models for these studies. We have used
a novel system, derived by sequential introduction of
a temperature-sensitive SV40 large T antigen and
oncogenic H-ras, to study the angiogenic switch.
The results from our studies differ from those using
NIH3T3 cells, but have been con®rmed by multiple
other groups. The data from all of these studies sug-
gest that there is synergy between inactivation of the
p53 tumor suppressor gene and activation of the
phosphoinositol-3-kinase pathway (PI-3-K), as well
as synergy between inactivation of the p16 tumor
suppressor gene and activation of the MAP kinase
pathway. These ®ndings suggest that there are pre-
dictable behaviors of tumors that may be assessed by
the status of p53 or p16 in a biopsy, and that these
predictable changes in signal transduction may be
useful both prognostically and in the design of
rationally based drug therapy of benign and malig-
nant tumors. Key words: angiogenic switch/growth
factors/ras/tumor suppressors. Journal of Investigative
Dermatology Symposium Proceedings 5:79±82, 2000
EVIDENCE THAT ONCOGENES AND GROWTH
FACTORS UTILIZE AT LEAST TWO SIGNAL
TRANSDUCTION PATHWAYS IN NORMAL CELLS
One of the paradigms of oncology is that tumors may arise from the
deregulation of growth factors, and the overexpression of
oncogenes. These mechanisms include the mutation of growth
factor receptors into constitutively active forms that can result in
transformation, both in vitro and in vivo. Some growth factors signal
through known oncogenes, such as members of the ras family.
What is less understood is that many, if not all of these growth
factors and oncogenes, when activated, are capable of signaling
through two distinct downstream pathways, the mitogen-activated
protein (MAP) kinase and the phosphoinositol-3-kinase (PI-3-K)
pathways (Fig 1). All normal primary cells appear to respond to the
addition of growth factors by activating both pathways in a transient
form. Examples of dominant oncogenes that act similarly include
ras oncogenes (Khosravi-Far et al, 1998; Wennstrom and
Downward, 1999), src (Penuel and Martin, 1999), abl (involved
in myeloid malignancy; Raitano et al, 1997), erbB2/neu (involved
in breast cancer; Marte et al, 1995; Petit et al, 1997; Adam et al,
1998; Daly et al, 1999), polyoma middle T (which causes
hemangiomas in newborn animals; Whitman et al, 1985; Dahl
et al, 1998; Summers et al, 1998; Webster et al, 1998), and ret
(involved in papillary thyroid carcinoma; Szabo et al, 1994; van
Weering and Bos, 1998). Growth factors that activate these
pathways include platelet derived growth factor (PDGF)
(Choudhury et al, 1997; Conway et al, 1999), epidermal growth
factor (EGF) (Wennstrom et al, 1991), hepatocyte growth factor
(HGF) (Graziani et al, 1991; Furukawa et al, 1999), insulin/insulin
growth factor-1 (IGF-1) (Parrizas et al, 1997), colony stimulating
factor 1 (CSF-1) (Bourette et al, 1997; Fowles et al, 1998), and
oncostatin M (Soldi et al, 1994), a Kaposi's sarcoma growth factor.
The response to growth factors is governed by the presence of
receptors, which is regulated in a tissue-speci®c manner.
Endothelial cells are a good example of the relationships between
growth factors and oncogenes, as they exist as benign, regressing
hemangiomas, as well as highly malignant angiosarcomas. We will
present evidence that hemangiomas arise from local imbalances of
angiogenic growth factors, whereas angiosarcomas arise from
constitutive deregulation of signal transduction pathways.
The two growth factors that appear to have the primary
regulatory functions of endothelium are basic ®broblast growth
factor (bFGF) and vascular endothelial growth factor (VEGF)
(Yoshida et al, 1996). bFGF signals through four known receptors,
FGFR1±4, of which FGFR1 plays the major role in endothelium.
VEGF signals through VEGFR1±2, of which VEGFR2 plays the
major role in endothelial chemotaxis and mitogenesis, whereas
VEGFR1 is implicated to play a role in lumen formation, and
serves as a receptor for placenta growth factor. BFGF is a major
endothelial mitogen.
The life cycle of a hemangioma is divided into three stages.
First is the initial, or proliferative stage, in which rapid growth
is noted. The second stage is the involuting stage, in which the
hemangioma decreases in size, and this is accompanied by
endothelial apoptosis. Finally, the hemangioma is at the
involuted stage, in which the hemangioma is replaced by scar
tissue (Takahashi et al, 1994).
One of the etiologies postulated to give rise to hemangiomas is a
local loss of alpha interferon (IFNa). IFNa is a angiogenesis
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inhibitor that was ®rst described to inhibit endothelial chemotaxis
(Brouty-Boye and Zetter, 1980). A second activity ascribed to
IFNa is inhibition of bFGF synthesis (Singh et al, 1995). IFNa is
now used clinically in the treatment of refractory hemangiomas,
and its action may be due to both downregulation of endothelial
chemotaxis and downregulation of bFGF synthesis.
A murine model of hemangiomas has been generated through
infection of neonatal or embryonal endothelium with polyoma
virus (Bautch et al, 1987; Williams et al, 1989). Polyoma virus
encodes a viral oncogene, polyoma middle T (PyMT), which
stimulates both MAP kinase and PI-3-K. Tumors derived from
these endothelium consist mostly of normal host endothelium,
interspersed with a small quantity of transformed endothelium. This
model of endothelial tumorigenesis is called host recruitment, as
most of the cells in the tumor are normal host endothelium. These
tumors may regress in a signi®cant number of mice, as they grow
older. Interestingly, culture of endothelial cells from human
hemangiomas has yielded only normal endothelium (Mulliken
et al, 1982). Thus host recruitment is likely the mechanism through
which human hemangiomas arise.
In contrast to hemangiomas, angiosarcomas are highly malignant
endothelial tumors that usually arise in adults after a carcinogenic
exposure, which may include ultraviolet light, radiation, chemical
toxins (vinyl chloride, Thorotrast), and lymphedema (Hollstein et al,
1994; Zietz et al, 1998). The majority of studied cases have been
shown to have loss of function of p53, either through mutation or
ampli®cation of mdm2, an oncogene that inactivates p53 (Marion
et al, 1991). Vinyl chloride-induced angiosarcomas in rats and
humans have been shown to have activating ras mutations. In order
to study the angiogenic switch in angiosarcomas, we have
sequentially introduced a temperature sensitive SV40 large T
antigen, which inactivates p53 and oncogenic H-ras. Endothelial
cells expressing large T antigen alone (MS1 cells) form cellular
hemangiomas in nude mice, which are dormant, and have a very
low proliferation and apoptosis rate, and introduction of H-ras
(SVR cells) results in aggressive angiosarcomas capable of metastatic
growth (Arbiser et al, 1997).
We have shown that ras upregulates the angiogenic switch in
these cells, resulting in increased expression of the proangio-
genic molecules VEGF and matrix metalloproteinases (MMP),
and downregulation of the endogenous inhibitors of angiogen-
esis tissue inhibitor of matrix metalloproteinase (TIMP) (Arbiser
et al, 1997). Gene chip analysis has shown that other stimulators
are upregulated by H-ras and potential inhibitors are down-
regulated by H-ras (Arbiser et al, manuscript in preparation).
We have shown that the PI-3-K pathway plays a major role in
the regulation of the angiogenic switch in this system, and
inhibition of PI-3-K signaling results in downregulation of
VEGF and MMP biosynthesis (Fig 2). The importance of PI-3-
K signaling has been con®rmed by other investigators, most
recently in immortalized porcine endothelial cells (Chang et al,
1997; Wang et al, 1999).
The angiogenic switch has been studied in other systems.
Oncogenic ras is capable of inducing angiogenesis in immortalized
colon epithelial cells, and raf is capable of inducing angiogenesis and
tumorigenesis in immortalized NIH3T3 cells(Grugel et al, 1995;
Rak et al, 1995). Since ras is directly upstream of the MAP kinase
pathway, this shows that activation of the MAP kinase pathway
alone is suf®cient to induce angiogenesis and tumorigenesis in
NIH3T3 based systems(Cowley et al, 1994). Expression of a
dominant negative MAP kinase is suf®cient to cause loss of
tumorigenesis in ras transformed NIH3T3 ®broblasts (Qiu et al,
1995). These results are the opposite of what we have observed, in
which downregulation of MAP kinase does not result in loss of
tumorigenesis in SVR cells (LaMontagne, in press).
How can these ®ndings be reconciled? One difference is that
MS1 endothelial cells are functionally de®cient in p53, due to the
action of SV40 large T antigen, whereas NIH3T3 cells are de®cient
in p16, another tumor suppressor gene (Linardopoulos et al, 1995).
Thus, in the presence of p16 de®ciency, MAP kinase activation is
oncogenic, whereas in p53 de®cient MS1 endothelial cells, MAP
kinase activation may have tumor suppressive activity (Figs 2, 3).
Several lines of evidence point towards separate and mutually
exclusive pathways of signal transduction activation. In gliomas,
two subsets have been observed. First, a high grade diploid tumor is
found in older individuals, and these tumors have been shown to
have loss of p16. A lower grade, aneuploid tumor is observed in
younger individuals, and these tumors have loss of p53 (Holland
et al, 1998a, b). Loss of both p53 and p16 are uncommon in the
same primary tumor. In the skin, the overwhelming majority of
squamous cell carcinomas appear to have p53 mutations, especially
with UV speci®c ``signature'' mutations. In contrast, cutaneous
melanoma cells appear to have a preponderance of p16 mutations,
and p53 mutations are relatively uncommon in cutaneous
melanoma. Oncogenic ras is capable of transforming cells that are
de®cient in either p53 or p16, but not normal cells (Serrano et al,
1997; Chin et al, 1999). Expression of oncogenic ras in normal cells
leads to increased expression of both p16 and p53, and senescense.
Thus p53 and p16 serve as safeguards to transformation by ras.
Similarly expression of MAP kinase in normal cells leads to elevated
expression of p16 and senescence (Lin et al, 1998; Zhu et al, 1998).
These observations point to mutual exclusion of p53 and p16 in
primary tumors. Data from other laboratories point towards
preferential use of signal transduction pathways as second hits.
The ras oncogene has been mutated to create genes that speci®cally
activate the MAP kinase or PI-3-K pathways, and the ability of
these genes to transform NIH3T3 cells was examined. Ras genes
Figure 1. Dual regulation of MAP kinase and PI-3-K in normal cells
by growth factors and oncogenes.
Figure 2. Regulation of the PI-3-K pathway by growth factors and
oncogenes in p53 de®cient cells.
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that caused preferential activation of the MAP kinase pathway were
more effective in induction of transformation and metastasis than
ras genes that preferentially activated PI-3-K. These experiments
will have to be repeated in other cell types with known tumor
suppressor mutations in order to generalize; however, if these
observations hold true, it will be possible to predict which signal
transduction pathway is activated in a primary tumor by
immunohistochemical staining for p53 and p16. This knowledge
will guide therapy, especially when signal transduction inhibitors
are used as therapy.
RELEVANCE OF TRANSIENT VERSUS SUSTAINED
SIGNAL TRANSDUCTION IN PRIMARY CELLS
Signal transduction pathways are activated transiently in numerous
physiologic processes. These include wound healing, in which
bFGF and VEGF are synthesized and released by the wounding
process, leading to a transient increase in angiogenesis until the
wound is healed. Other examples include changes in the breast
epithelium in response to pregnancy, and response of hematopoie-
tic cells to growth factors. Overactivity of signal transduction
pathways on a sustained basis are seen in all malignancies, but what
is not as well realized is the contribution of signal transduction
pathways in benign tumors. We have previously shown that the
development of tumors requires two events. First, the cells must
have the ability to proliferate in three dimensions. Second, they
must have the ability to stimulate angiogenesis. One of the most
relevant examples of signal transduction abnormalities in benign
tumors is neuro®bromatosis type 1 (NF1).
NF1 results from a mutation in the neuro®bromin gene,
which regulates a ras GTPase. Mutation in neuro®bromin
results in functional hyperactivity of ras. This gives rise to
Schwann tumors that are benign, but highly angiogenic (Arbiser
et al, 1998). These tumors are not known to have mutations in
the tumor suppressor genes p53 and p16. Highly angiogenic
benign tumors are not limited to NF1. Benign tumors are
observed in the autosomal disorder tuberous sclerosis, which
also has abnormalities in ras related signaling pathways, and may
be present in numerous other benign neoplasms of the skin,
including seborrheic keratosis and Spitz nevus. Other genetic
disorders, such as Cowdens disease, which exhibits benign
tumors of the skin, as well as thyroid and breast carcinoma, has
mutations in the PTEN/MMAC gene, which is a protein
phosphatase. When this phosphatase is mutated, the PI-3-K
pathway is upregulated (Stambolic and Suzuki, 1998; Cantley
and Neel, 1999). We predict that in these benign tumors,
which have activation of signal transduction pathways, will be
highly angiogenic. A second hit, i.e., loss of the tumor
suppressor genes p53 or p16, may result in conversion to
malignancy, but not necessarily cause increased angiogenesis. On
the other hand, tumors that arise through loss of tumor
suppressor genes as a ®rst hit, such as the conversion of actinic
keratosis to squamous cell carcinoma, or atypical nevi to
melanoma, will demonstrate increased angiogenesis with tumor
progression (Fig 4). The further genetic hits that cause
malignant transformation in squamous cell carcinoma or
melanoma cause activation of signal transduction pathways
which upregulate angiogenesis stimulators and downregulate
angiogenesis inhibitors. Use of signal transduction inhibitors may
be useful in preventing the development of benign tumors in
genetic disorders, or treatment of existing disorders.
DOWNSTREAM TARGETS OF SIGNAL
TRANSDUCTION PATHWAYS: TARGETS FOR
INTERVENTION
Although there are numerous combinations of tumor suppressor
genes and dominant oncogenes that can lead to tumorigenesis,
there are certain common genes that appear to be activated in
most malignancies. These include MMP, VEGF, bFGF,
urokinase/tissue plasminogen activator, and expression of
antiapoptotic integrins. The transcription and translation of
these genes appears to be under control of speci®c transcription
factors and translational control. A limited repertoire of
homeobox genes appear to be upregulated in malignant
transformation, and these include Hox A7 and Hox B7
(Chariot et al, 1999). Another gene that appears to have a
crucial function in regulating translation of growth factors is the
translation factor EIF-4E (Kevil et al, 1996). These factors have
been shown to regulate transcription and translation of
angiogenesis factors, and may be upregulated in both in¯am-
matory and malignant angiogenic disorders. Further study of
these molecules is warranted, as existing drugs may regulate
these molecules in ways that may be therapeutically bene®cial.
In addition, novel screening techniques will need to be
developed in order to perform high throughput screening for
inhibitors of signal transduction pathways and transcription
factors, such as Hox A7 and Hox B7. Finally, further
experiments must be performed to con®rm the relationship
between p53 and PI-3-K, and p16 and MAP kinase. If our
predictions hold true, knowledge of the status of p53 function
or p16 function of a primary tumor will enable the clinician to
Figure 3. Regulation of the MAP kinase pathway by growth factors
and oncogenes in p16 de®cient cells.
Figure 4. Two-hit hypothesis with reference to tumor angiogenesis.
In neuro®bromas, the ®rst genetic hit is increased ras activation, so the
benign tumors are already angiogenic. The second hit is loss of p53, which
may result in only a slight increase in angiogenesis. In contrast, in
melanoma progression, the ®rst hit is loss of p16, which may not result in
increased angiogenesis, but ras activation as a second hit will result in
upregulation of angiogenesis.
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predict which signal transduction pathway is hyperactive and to
design appropriate therapy.
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